Navigation Links
Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results
Date:11/3/2011

Net cash provided by operating activities

7,692,0581,033,102Cash flows from investing activities:Additions to property and equipment

(241,885)(311,301)Additions to patents

(140,356)(132,047)Net cash used in investment activities

(382,241)(443,348)Cash flows from financing activities:Principal payments on note payable

(5,333,333)(12,000,000)Net borrowings on line of credit

2,750,000-Costs of financing for long-term debt and credit facility

-(82,500)Proceeds from exercise of stock options

681,6341,182,139Excess tax benefit derived from exercise of stock options

2,657,2591,256,913Repurchase of common shares

(2,884,540)(4,129,648)Net cash used in financing activities

(2,128,980)(13,773,096)Net increase (decrease) in cash and cash equivalents

5,180,837(13,183,342)Cash and cash equivalents at beginning of period

65,893,97078,701,682Cash and cash equivalents at end of period

$
71,074,807$
5,518,340Supplemental disclosure of cash flow information:Non-cash investing and financing activities:Common shares repurchased during period but not paidas of the end of the period

-22,207
'/>"/>

SOURCE Cumberland Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Cumberland Pharmaceuticals Taps Industry Veteran for Key Executive Position
2. Neurotech Announces the Opening of Its GMP Manufacturing Facility in Cumberland, Rhode Island
3. Cumberland Pharmaceuticals Appoints Lee Product Director
4. Cumberland Emerging Technologies and UT Research Foundation Sign License Agreement for New Technology
5. Cumberland Pharmaceuticals Provides Hospital In-Service Webcast for Acetadote(R)
6. Cumberland Pharmaceuticals Announces FDA Approval of Caldolor(TM)
7. Cumberland Pharmaceuticals Announces Pricing of Its Initial Public Offering of Common Stock
8. Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
10. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
11. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... , Oct. 20, 2014 Asterias ... the Company has signed a Notice of Grant ... Medicine (CIRM), effective October 1, 2014.  The NGA ... payments and the release of additional grant funds ... grant award for clinical development of Asterias, product, ...
(Date:10/20/2014)... , Oct. 20, 2014  GenVec, Inc. (NASDAQ: ... P. Horovitz , Ph.D., from its board of directors effective ... in August 2003, and served as its chairman from June ... on the Nominating and Corporate Governance and Audit Committees of ... more than a decade of dedicated service to GenVec, and ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 ... Partners LLC, announced today that Ellen Teplitzky, an ... support for the pharmaceutical industry, has joined the ... of its legal services practice. NDA Partners ... expert witness and testimony, to top law firms ...
(Date:10/19/2014)... 2014 OCTOBER 20-22, 2014: ... ABIM will take place at the ... ABIM 2014 is now available at ... companies and organizations from all over the ... on the latest products and developments on ...
Breaking Biology Technology:Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4Zola P. Horovitz To Retire From GenVec Board 2NDA Partners Appoints Ellen Teplitzky, JD as Director of its Legal Services Practice 2
... ... office , ... Ill. (Vocus) December 9, 2009 -- As part of ongoing efforts to expand deployment ... in the contaminated soil , sediment and groundwater remediation industry, is ...
... , , WALTHAM, Mass., Dec. 8 ... Company President and Chief Executive Officer, Walter C. Herlihy, Ph.D., will ... at 8:30 a.m. EST, to discuss results of its Phase 3 ... , This call is being webcast by Thomson/CCBN and can ...
... , CLEVELAND, ... high-performance products to the market with a Smart ... performance and recyclable packaging, Nutek,s products continue to ... , (Photo: http://www.newscom.com/cgi-bin/prnh/20091208/CL22934 ) ...
Cached Biology Technology:Olympics 2016, World Cup 2014, But First – Adventus Brasil 2009 2Olympics 2016, World Cup 2014, But First – Adventus Brasil 2009 3Olympics 2016, World Cup 2014, But First – Adventus Brasil 2009 4Repligen Announces Conference Call to Discuss Phase 3 Clinical Trial Results of RG1068 in MRI Imaging of the Pancreas 2Repligen Announces Conference Call to Discuss Phase 3 Clinical Trial Results of RG1068 in MRI Imaging of the Pancreas 3Nutek, LLC Introduces New Soy-Based, Biodegradable Lubricating and Cleaning Wipes 2
(Date:10/14/2014)... (Oct. 14, 2014)—It,s been millions of years since ... team led by Ohio University scientists is breathing life ... airflow through dinosaur snouts. The research has important implications ... breathe but to enhance the sense of smell and ... animals," said Ohio University doctoral student Jason Bourke, lead ...
(Date:10/14/2014)... new kind of stem cell that can become either a ... according to a study published today in the journal ... type contradicts current theory on how organs arise from cell ... of, and future treatment for, liver cancer., Thanks to stem ... being made up of more than 200 cell types. The ...
(Date:10/14/2014)... MA – A team of scientists led by ... (UMMS) and the University of Miami Miller School ... a key genetic pathway underlying bipolar (manic depressive) ... drugs for treating bipolar affective disorder, as well ... The new findings, published online this week in ...
Breaking Biology News(10 mins):Dinosaur breathing study shows that noses enhanced smelling and cooled brain 2Dinosaur breathing study shows that noses enhanced smelling and cooled brain 3Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 2Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 3Rare genetic disease protects against bipolar disorder 2Rare genetic disease protects against bipolar disorder 3
... Now, a St. Louis-area teenage boy and a computer ... conducted by a team of neurosurgeons, neurologists, and engineers ... boy, a 14-year-old who suffers from epilepsy, is the ... Invaders, using only the signals from his brain to ...
... In a study appearing in the forthcoming issue of ... Tyre, and Svata M. Louda (all of the University ... aren't all eaten at the same rate. , ... the nutritional quality or defective chemistry of plant tissues. ...
... speed healing at sites of injury - such as heart ... stroke - doctors would like to be able to hasten ... to "mobilize" patients' blood vessel-forming cells, called angiogenic cells, so ... at Washington University School of Medicine in St. Louis demonstrated ...
Cached Biology News:Teenager moves video icons just by imagination 2Teenager moves video icons just by imagination 3Drug can quickly mobilize an army of cells to repair injury 2